TABLE OF CONTENTS

GRAPHICS

Table of Contents

35. Totality Of Evidence in Floor Effect Subgroup Consistent Across Endpoints
36. Totality Of Evidence in Floor Effect Subgroup Consistent Across Domain Subscales
37. Totality Of Evidence in Floor Effect Subgroup Consistent Across Endpoints
38. Secondary Endpoints by Cut-point ≥ 26 to ≥35
39. Primary Endpoint: No Floor Effect Subgroup and ≥ 27 Subgroup
40. Secondary Endpoint: No Floor Effect Subgroup and ≥ 27 Subgroup
41. Tofersen Change from Baseline at 28 weeks
42. Tofersen vs. NurOwn: Change from Baseline at 28 weeks
43. NurOwn Primary & Secondary Endpoint ≥35 Demonstrating Stabilization
44. NurOwn's Phase 2 Trial Results
45. NurOwn's Phase 2 Trial Results ≥100% Improvement in Slope in Rapid Progressors
46. Tofersen's Phase 3 Survival Data in A5V Rapid Progressors
47. Eric Stevens' ALSFRS-R Phase 3 and EAP
48. Josh Smith's ALSFRS-R scores in Phase 3 and EAP
49. Kade Simons' ALSFRS-R scores in Phase 3 and EAP
50. Lesley Krummel's ALSFRS-R scores in Phase 3 and EAP
51. Justin Rogers' Bulbar Survival versus Median Survival from Diagnosis
52. Right to Try Bill Signing with Matt Bellina and Nicole Cimbura
53. Tara Collazo's ALSFRS-R scores by Domain
54. Military Medicine Study regarding Post 9/11 Veterans and ALS
55. Matt Bellina's Real-World Data
56. WLWT Broadcast: Fighting for Their Lives
57. Time-to-Event Data in ALS
58. Time-to-NIV
59. Josh Smith's FVC Tests 2020 Pre-EAP vs. 2021 Post-EAP
60. FVC Tests 2021 vs. 2022 Post-EAP for Eric Stevens and Phil Green
61. NurOwn CSF Biomarkers across 3 Primary Pathways
62. NurOwn CSF Biomarkers PCA across 3 Primary Pathways
63. NurOwn Biomarker Changes (Table S3 in Muscle & Nerve)
64. Totality of CSF Biomarker Evidence Supports Mechanism of Action
65. FDA Slides about Neurofilament Light from Tofersen AdComm
66. NurOwn's Neurofilament Light Results from Phase 3
67. NurOwn's Neurofilament Light Results from Phase 3 and EAP
68. NurOwn's Neurofilament Light Results from Early Start vs Delayed Start in EAP
69. NurOwn's Neurofilament Light Results - Percentage of Change Bar Chart
70. NurOwn's Neurofilament Light Results - Percentage of Change - by Participant
71. Neurofilament Light Pattern Changes - NurOwn vs. Tofersen
72. UNC13A and the 66 Mis-splicing Genes in ALS
73. UNC13A in ALS GWAS

74. UNC13A (A/C) Responder Analysis in NurOwn Phase 3 Trial
75. FDA's Presentation Slide of Neurotrophic Factors for ALS Treatments
76. Neurotrophic Factors for ALS: BDNF, GDNF, EGF and HGF
77. NurOwn's Phase 3B Trial Design
78. NurOwn Timeline
79. Tukysa Partial Response
80. Vitrakvi
81. ALS KOL, Mayo's Dr. Windebank AdComm Testimony that NurOwn Works
82. NurOwn's Totality of the Evidence: p-values by endpoint and cut-point
83. Post Hoc Data Used in all Four ALS Drug Approvals
84. Tofersen Post Hoc Data Accepted
85. PFDD – Patient Experience
86. C-Path's COAs: Patient Experience and PFDD
87. Phase 2 and 3 Data Confirms Some Patients Halted Progression
88. FDA's Regulatory Flexibility Slide from Tofersen AdComm
89. Plausible MOA: Stem Cell Trials in ALS
90. Plausible MOA: Stem Cell Trials in Other Neurodegenerative Diseases
91. Risk-Benefit: Risk of Type II Errors
92. Heterogeneity in ALS Trials and Impact on Trial Outcomes
93. Heterogeneity: SETX-VUS
94. Gene-Time-Environment Hypothesis
95. Genetic Risk and ALS Exposome
96. Genetic Risk and ALS Exposome Natural History Database
97. Prospective ALS Exposome Natural History Database
98. NurOwn Phase 3 Trial Participant Betsy McCormick on Cancelled EAP